possible (antinociceptive) effect; Δ 9 -THC = Δ 9tetrahydrocannabinol; WIN55,212-2 = ([(3R)-2,3-dihydro-5-methyl-3-(4morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate)
Introduction
In the 1960s, Raphael Mechoulam's isolation and elucidation of the chemical structure of Δ 9 -tetrahydrocannabinol (Δ 9 -THC) (Gaoni and Mechoulam, 1964) , the primary psychoactive substituent in Cannabis sativa, initiated a concerted effort directed at manipulation of its chemical structure, with one goal being to produce a compound with medicinal effects and no psychoactive properties. Synthesis of phytocannabinoid analogs was followed by development of bicyclic cannabinoids (e.g., CP55,940) and aminoalkylindoles (e.g., WIN55,212-2). The effort was renewed with the discovery and initial characterization of the endocannabinoid system (Devane et al., 1988) , which added the structural templates of arachidonic acid derivative agonists (anandamide and 2-arachidonoylglycerol) (Devane et al., 1992; Hanus et al., 2001 ) and a pyrazole antagonist, rimonabant (Rinaldi-Carmona et al., 1994) . Structure-activity relationship studies focused on delineation of the ways in which these diverse chemical structures could bind to the two identified cannabinoid receptors (CB 1 and CB 2 ) and differentiation of features which might enhance selectivity for the CB 2 cannabinoid receptor. CB 1 receptor mediation of the marijuana-like psychoactive effects of cannabinoids was confirmed during this time (Wiley et al., 1995b) , and the high correlation between binding affinity and potency for producing these psychoactive effects in mice was noted (Compton et al., 1993) . The systematic synthesis of cannabinoids for use as research tools to probe the structure and functioning of the cannabinoid receptors or for use as lead candidates in medication development efforts continued to produce a multitude of novel synthetic cannabinoids (e.g., see Manera et al., 2008) . After the initial publication of this medicinal chemistry research, much of it lay dormant, with the exception of occasional retrieval by scientists.
Then, in the 2000s, several of of the previously reported compounds were identified in confiscated "herbal incense" labeled as "Spice" (Vardakou et al., 2010) . Largely due to the rapid This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on June 23, 2015 as DOI: 10.1124/jpet.115.225326 at ASPET Journals on November 4, 2016 jpet.aspetjournals.org Downloaded from proliferation of information through the internet, the use of JWH-018 and other research chemicals for their intoxicating effects was spreading throughout the world. Legal bans of the cannabinoids contained in early products resulted in the emergence of additional compounds not yet illegal, creating a type of "whack a mole" situation between drug control agencies and illicit manufacturers. For example, prevalence of JWH-018 faded as it was subsequently replaced by AM-2201 and then, by tetramethylcyclopropyl ketone indoles . Most recently, two indazole carboxamide cannabinoids, AB-CHMINACA and AB-PINACA, have achieved prominence, resulting in their temporary placement into Schedule I (i.e., compounds with high abuse potential and no accepted medical use) by the U.S. Drug Enforcement Agency (U.S. Drug Enforcement Administration, 2015) . An associated problem with the rapid proliferation of synthetic cannabinoids is detection and identification of their metabolites in biological fluids. This forensic information is often helpful for detection of use for the purposes of medical treatment, employee screening, or legal prosecution.
The purpose of the present study was to examine the in vitro and in vivo pharmacology of AB-CHMINACA and AB-PINACA ( Figure 1) . FUBIMINA, an analog of a previously identified synthetic cannabinoid of abuse, AM-2201, was also evaluated (Figure 1 ). Assessment centered on assays used to predict the abuse liability of cannabinoids (Wiley and Martin, 2009) , including binding and activation of CB 1 receptors, pharmacological equivalence with Δ 9 -THC in a battery of four tests in mice, and Δ 9 -THC discrimination in mice. In the Δ 9 -THC discrimination procedure, results are also presented for synthetic cannabinoids from different chemical classes, including the prototypic indole-derived synthetic cannabinoid JWH-018, a bicylic cannabinoid CP47,497, and the aminoalkylindole WIN55,212-2. These representative compounds are from different chemical classes of cannabinoids which have been well-This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on June 23, 2015 as DOI: 10.1124/jpet.115.225326 at ASPET Journals on November 4, 2016 jpet.aspetjournals.org Downloaded from characterized previously (Compton et al., 1992a; Compton et al., 1992b; Wiley et al., 1998) .
They were tested here to provide a basis for comparison with the structurally innovative compounds shown in Figure 1 . To assist in the development of forensic markers and to examine metabolic transformations, preliminary analysis of urinary metabolites of the three novel synthetic cannabinoids also was undertaken.
This article has not been copyedited and formatted. The final version may differ from this version. 
Experimental Procedures
All in vitro and in vivo experimental procedures were similar to those described in our previous publication (Wiley et al., 2013) , in which we described results of tests with two tetramethylcyclopropyl ketone indoles, XLR-11 and UR-144, that are also classified as synthetic cannabinoids of abuse.
Receptor Binding
Transfected cell membrane preparations with human CB 1 (hCB 1 ) and human CB 2 (hCB 2 ) receptors (Perkin Elmer, Waltham, MA) isolated from a HEK-293 expression system were used for cannabinoid binding assays, as previously described (Zhang et al., 2010 
Mouse Tetrad
Each mouse was tested in a tetrad of tests, in which cannabinoid agonists produce a profile of in vivo effects (Martin et al., 1991) : suppression of locomotor activity, decreased rectal temperature, antinociception, and catalepsy. Prior to injection, baseline values were obtained for rectal temperature and in the tail flick test in each mouse. In the latter procedure, the mouse's tail was placed under an intense light (radiant heat) and the latency to remove it (in s) was recorded.
In order to minimize tail damage, a 10-s maximal latency was employed. After baseline measurements were taken, mice were injected intraperitoneally (i.p.) with vehicle or drug 30 min before being placed into individual activity chambers for a 10-min session. Immediately upon removal from the chambers, tail-flick latency and rectal temperature were measured again followed by placement on the elevated ring apparatus at 50 min post-injection. The amount of time the animals remained motionless on the ring during a 5 min period was recorded. If a mouse fell off the ring during the catalepsy test, it was immediately placed back on and timing was continued for up to 9 falls. After the 10th fall, the test was terminated for the mouse.
At least one week after completion of all agonist tests, combinations of vehicle or 3 mg/kg rimonabant and active doses of each compound (56 mg/kg Δ 9 -THC, 3 mg/kg AB-CHMINACA, and 30 mg/kg AB-PINACA) were re-tested in a subset of the same mice.
Procedural details were identical to those described above, with the exception that mice received an i.p. injection of vehicle or rimonabant 10 min prior to i.p. injection of the agonist test compound.
Because FUBIMINA was not active at doses up to 100 mg/kg, i.p., a probe dose of 56 mg/kg (and vehicle) was administered i.v. to separate groups of mice. Evaluation in the tetrad tests proceeded as described above, with the exception that mice were placed into the locomotor chambers five min after injection and placed on the ring apparatus, 25 min post-injection.
Subsequently, the effect of 3 mg/kg rimonabant (i.v.) in combination with the 56 mg/kg dose (i.v.) of FUBIMINA was assessed. Rimonabant was injected 10 min prior to FUBIMINA or vehicle.
Drug Discrimination
Two groups of adult male mice were trained to discriminate Δ 9 -THC in standard operant chambers, as described previously (Vann et al., 2009) . Mice were trained to press one of two levers following i.p. administration of 5.6 mg/kg Δ 9 -THC and to press the other lever after i.p.
vehicle injection. Ten consecutive responses on the correct (injection-appropriate) lever resulted in delivery of a food pellet [i.e., fixed ratio 10 (FR10)] whereas responses on the incorrect lever reset the ratio requirement on the correct lever. A double alternation sequence of Δ 9 -THC and vehicle (e.g., drug, drug, vehicle, vehicle) was instituted. Fifteen min training sessions were held Monday-Friday until the mice consistently met three criteria: (1) the first completed FR10 was on the correct lever, (2) ≥ 80% of the total responding occurred on the correct lever, and ( in both groups of mice. The first group of mice was subsequently tested with several cannabinoid tricyclic dibenzopyran analogs (data not shown) and with two indole-derived synthetic cannabinoids (Wiley et al., 2013) . In the present study, the first group of mice were tested with JWH-018, WIN55,212-2, and CP47,497, and a second dose-effect curve was determined Δ 9 -THC.
The second group of mice was tested with several noncannabinoid compounds (data not shown). Subsequently, their response requirement was changed from lever presses to nose pokes. This change was necessitated by transition of all of the lab's mouse operant equipment to nose poke apertures and was not specifically related to this study. Additional mice were trained de novo on the nose poke response (using the acquisition procedure described above) and were combined with this second group of mice. With the exception of the actual response (nose poke vs. lever press), all other procedural details remained the same (e.g., FR10, food reinforcement, testing criteria). After acquisition of the nose poke response, a dose-effect curve with Δ 9 -THC was determined (i.e., for de novo mice) or re-determined (i.e., for transition mice) followed by dose-effect curve determinations with AB-PINACA, AB-CHMINACA, and FUBIMINA.
Metabolite Analysis
Twelve mice (n=4 per drug) were given i.p. injections of 3 mg/kg AB-PINACA, 3 mg/kg AB-CHMINACA, or 100 mg/kg FUBIMINA. Immediately following injections the mice were placed into metabolism cages and urine was collected over a 24 hour period. Urine from mice dosed with the same compound was pooled for analysis. Samples were extracted using a salting out liquid-liquid extraction (SALLE) method prior to analysis. Acetonitrile (200 µL) was added to 100 µL of urine, then the samples were vortexed and 50 µL of 5 M ammonium acetate was This article has not been copyedited and formatted. The final version may differ from this version. added as a salting out agent. Samples were vortexed and centrifuged at 10,000 rcf for 5 min. The top aqueous layer was removed and dried down at 40 °C and reconstituted with 50 µL of mobile phase A.
Samples were analyzed on a Waters Acquity ultra performance liquid chromatography (UPLC) system coupled to a Waters Synapt G2 HDMS quadrupole time-of-flight (Q-TOF) mass spectrometer (Waters, Milford, MA). The mass spectrometer was operated under resolution mode, positive electrospray ionization, source temperature of 150 °C, desolvation temperature of 500 °C , desolvation gas at 1,000 L/hr, capillary voltage at 2.99 kV, sampling cone at 35 V, and extraction cone at 4.3 V. The mass spectrometer was externally calibrated from 50 -1000 m/z using a sodium formate solution. Leucine enkephalin was used as a lockmass to correct for mass shifts during acquisition. Full scan data was collected in both low (4 eV) and high (15 to 40 eV ramp) collision energies nearly simultaneously for every m/z using MS E acquisition mode (Bateman et al., 2002) .
Samples were separated on an Acquity BEH C18 column (1.7 μ m 2.1 x 50 mm) connected to a Vanguard BEH C18 pre-column (1.7 µm x 2.1 X 5 mm) and held at 30 °C.
Injection volume was 10 µL. A gradient elution with a flow rate of 500 µL/min was used with mobile phase A consisting of water with 0.1% formic acid and mobile phase B consisting of acetonitrile with 0.1% formic acid. The mobile phase composition for AB-PINACA and AB-CHMINACA was held at 90% A for 1.5 min, decreased to 55% A over 15 min, decreased to 5%
A over 3 min and held at 90% A for 2.9 min for column re-equilibration. For FUBIMINA the gradient was held at 90% A for .5 min, decreased to 85% A over 1 min to 35% A over 15 min, then to 5% A over 3 min and held at 90% A for 2.9 min for column re-equilibration. For EG-18,
The gradient was held at 90% A for 0.5 min, decreased to 65% A over 1 min and 35% A over 13 min, then decreased to 5% A over 5 min and held at 90% A for 2.9 min for column reequilibration. All mobile phase composition changes were done linearly.
Drugs and Chemicals
-phenol] and rimonabant (the prototypic CB 1 receptor antagonist/inverse agonist) were obtained from the National Institute on Drug Abuse Since mice that responded less than 10 times during a test session did not respond on either manipulandum a sufficient number of times to earn a reinforcer, their data were excluded from analysis of drug manipulandum selection, but their response rate data were included. Responserate data were analyzed using repeated-measures ANOVA across dose. Significant ANOVAs were further analyzed with Tukey post hoc tests (α = 0.05) to specify differences between means.
Metabolite Identification
LC-MS data was analyzed using Waters MassLynx 4.1 with the aid of the MetaboLynx application manager. Automated data processing with MetaboLynx was supplemented by manual interrogation of the data using mass defect filtering, precursor ion and fragment ion searching techniques (Grabenauer et al., 2012) . Presence of potential metabolites was determined by exact mass match to predicted elemental compositions in the low energy data function. Further refinement of the site of modification was determined by presence of characteristic fragment ions at the same retention time. Metabolites were provisionally identified by their molecular weight, retention time, and fragment ions. Metabolites were compared to reference standards as available. 
Results

Cannabinoid Receptor Binding and Agonist-Stimulated [ 35 S]GTPγS Binding
All three test compounds displaced [ 3 H]CP-55,940 at the CB 1 receptor binding site (Figure 2, panel A) , but with varying affinities which ranged from inhibition constants ( i ) 0.59 nM for CP55,940 to 296 nM for FUBIMINA (Table 1) . In contrast, only two of the three test compounds (AB-CHMINACA and AB-PINACA) stimulated GTP-γ-[ 35 S] turnover with reasonable potency (Figure 2, panel B) . Rank order of potency was AB-CHMINACA > CP55,940 > AB-PINACA (Table 1) . Further, AB-CHMINACA and AB-PINACA exhibited enhanced efficacy compared to CP55,940 ( Figure 2, panel B) , it did so only at very high concentrations (Table 1 ), suggesting it serves as a weakly potent agonist at the CB 1 receptor.
Similar to their effects at the CB 1 receptor, all three test compounds displaced [ 3 H]CP-55,940 at the CB 2 receptor binding site (Figure 2 , panel C). Further, affinities of all compounds for the CB 2 receptor exceeded those obtained at the CB 1 receptor by 1.7-to 12.6-fold (Table 1) [main effect of receptor type for k i : F(1,24)=60.37, p<0.05]. In contrast with the greater affinities of the test compounds for the CB 2 receptor, they showed reduced efficacy at this receptor compared to the CB 1 receptor (Figure 2, In contrast, FUBIMINA did not affect spontaneous activity or rectal temperature and did not produce ring immobility at i.p. doses up to 100 mg/kg (Figure 3 ). Although i.p. doses of 30 and 100 mg/kg FUBIMINA produced statistically significant increases in antinociception, the magnitude of these increases was small and did not approach the maximal effects observed with 
Drug Discrimination in Mice
Mice trained to lever press for food reward in a Δ 9 -THC discrimination procedure showed full dose-dependent substitution for the 5.6 mg/kg Δ 9 -THC training dose ( Figure 5 , top panel), with a potency similar to that obtained with mice trained in the nose poke procedure (Table 3) As shown in Figure 6 (panel C), AB-CHMINACA and AB-PINACA produced full, dosedependent substitution for Δ 9 -THC. Both compounds were more potent than Δ 9 -THC by 16-and 1.5-fold for AB-CHMINACA and AB-PINACA, respectively (Table 3) . Of the two test compounds, the effects of AB-CHMINACA bore the most resemblance to those of The profile of AB-PINACA was distinct from that produced by Δ 9 -THC and AB-CHMINACA, in that full substitution was observed only at a dose (3 mg/kg; Figure 6 , panel C) that also severely reduced response rates [F(4,32)=16.48, p<0.05] (Figure 6, panel D) . Only 2 of 9 mice tested with this dose responded on either aperture. Further, the response rate dose-effect function was steep, with no effect at 1.7 mg/kg and nearly complete suppression at a dose (3 mg/kg) only ½ log higher ( Figure 6 , panel D).
Results of substitution tests with FUBIMINA revealed considerable variability in choice
of aperture across the mice. While FUBIMINA did not fully substitute for Δ 9 -THC (i.e., >80% Δ 9 -THC-aperture responding), dose-dependent increases in responding on the Δ 9 -THC aperture (partial substitution) were observed ( Figure 6 , panel C; Table 3 ). FUBIMINA did not significantly affect response rates ( Figure 6, panel D) .
Metabolite Identification
In A summary of the metabolites found in urine from mice dosed FUBIMINA is shown in 
Discussion
Psychoactive cannabinoid agonists produce a characteristic profile of in vitro and in vivo pharmacological effects, including binding to and activating CB 1 receptors, dose-dependent activity in a tetrad battery of tests in mice, and Δ 9 -THC-like discriminative stimulus effects (Wiley and Martin, 2009 ). In the present study, the in vitro positive control CP55,940 showed low nM K i for both CB 1 and CB 2 receptors, similar to a number of indole and pyrrole-derived synthetic cannabinoids (Huffman and Padgett, 2005; Wiley et al., 2014a) . Further, it stimulated [ 35 S]GTPγS turnover with high potency and efficacy at both receptors, suggesting that CP55,940 would act as a potent CB 1 receptor agonist in vivo. Indeed, this prediction has proved true, as CP55,940 produces cannabimimetic effects in the tetrad battery in mice (Compton et al., 1992b) and substitutes and cross-substitutes for Δ 9 -THC in drug discrimination in rats (Gold et al., 1992; Wiley et al., 1995a) . Similarly, the in vivo positive control Δ 9 -THC suppressed locomotor activity and showed hypothermic, antinociceptive, cataleptic and Δ 9 -THC-like discriminative stimulus effects in mice. Δ 9 -THC -like discriminative stimulus effects were also observed with JWH-018, WIN55,212-2, and CP47,497, as has been shown previously with the former two compounds (Compton et al., 1992a; Wiley et al., 2014b) and with the C-8 homolog of CP47,497 (Gatch and Forster, 2014) . Previous research has shown that these three compounds bind to the CB 1 receptor with high affinity and produce cannabimimetic effects in the tetrad battery (Compton et al., 1992a; Compton et al., 1992b; Wiley et al., 1998) . Together, these data show that representative compounds from the tetrahydrocannabinol, bicyclic and aminoalkylindole cannabinoid classes produce similar in vivo and in vitro pharmacological profiles in these assays.
In contrast, the three novel synthetic cannabinoids tested herein produced distinct profiles in the battery of in vitro and in vivo assays, with quantitative differences compared to typical showed higher CB 2 receptor affinity, FUBIMINA exhibited several-fold greater selectivity than AB-CHMINACA or CP55,940. Both compounds also activated CB 1 receptors with full efficacy comparable to (FUBIMINA) or greater than (AB-CHMINACA) that produced by CP55,940 (present study) or other full agonists such as WIN55,212-2 (Griffin et al., 1998) , albeit FUBIMINA showed limited potency that was consistent with its lower binding affinity.
Consistent with the magnitudes of their respective CB 1 receptor affinities, AB-CHMINACA produced the full profile of cannabinoid effects in the tetrad battery whereas FUBIMINA was inactive when administered i.p. and produced a cannabimimetic profile only at a 56 mg/kg i.v.
dose. Tetrad effects of AB-CHMINACA and FUBIMINA were attenuated by rimonabant, suggesting CB 1 receptor mediation. In Δ 9 -THC discrimination, 0.3 mg/kg AB-CHMINACA, a dose that did not affect response rates, fully and potently substituted for Δ 9 -THC. This pattern of results resembles that obtained with the control compounds from different chemical classes of cannabinoids (see Figure 6 ). In contrast, FUBIMINA only partially substituted for Δ 9 -THC and did so with considerable intra-subject variability. Although tested up to the limits of solubility, FUBIMINA failed to decrease response rates. Together, these results suggest that AB-CHMINACA is a potent and efficacious psychoactive CB 1 receptor agonist that is likely to possess abuse liability in humans, a finding that has been implicitly supported through its recent placement in Schedule I (U.S. Drug Enforcement Administration, 2015) . FUBIMINA also This article has not been copyedited and formatted. The final version may differ from this version. appears to share cannabimimetic effects with Δ 9 -THC; however, its low potency may limit its abuse, as illicit manufacturers tend to focus on compounds with greater CB 1 receptor affinity and high potency. Nevertheless, FUBIMINA has been detected in products in Japan (Uchiyama et al., 2014) and with sufficient concentrations, cannabimimetic effects are likely. Metabolic transformations observed for these compounds were similar to those described for many similarly structured synthetic cannabinoids and primarily consisted of monohydroxylation and glucuronide conjugation, with FUBIMINA also undergoing defluorination, as is typical for synthetic cannabinoids with a 5-fluoropentyl group (e.g., AM-2201).
While in vitro results showed that AB-PINACA resembled AB-CHMINACA in its high affinities for CB 1 and CB 2 receptors and its high efficacy for stimulation of CB 1 receptors, differences between their profiles emerged in the in vivo experiments. Both compounds produced rimonabant-reversible effects in the complete tetrad battery; however, administration of 30 mg/kg (i.p.) AB-PINACA was accompanied by short-lived convulsive behavior, an effect that we do not typically observe with Δ 9 -THC or other cannabinoids at doses that produce tetrad effects. In the Δ 9 -THC discrimination procedure, AB-PINACA substituted fully and dosedependently for Δ 9 -THC, but full substitution was achieved only at a dose that was accompanied by substantial decreases in response rate, with only a small percentage (22%) of mice responding at this dose. Previously, we have observed response rate decreases only with doses of other synthetic cannabinoids that were suprathreshold for full substitution (Figure 5 ; Wiley et al., 1995a; Wiley et al., 2013) . Hence, AB-PINACA's lack of separation between doses that were Δ 9 -THC-like and those that substantially suppressed responding was unusual compared to the profile seen with other synthetic cannabinoids. These results suggest that AB-PINACA is a potent psychoactive CB 1 receptor agonist, but they also suggest that the doses that induce intoxication may be very close to (or indistinguishable from) doses associated with behavioral toxicity.
In summary, synthetic cannabinoids that were originally developed as research tools or as candidate medications have been diverted to drugs of abuse in the form of products labeled with such terms as "herbal incense," "fake weed," "spice," and "K2. Showalter VM, Compton DR, Martin BR and Abood ME (1996) * ED 50 s (± 95% confidence limits) are expressed in μmol/kg. Molecular weights are provided in parentheses. All compounds were administered i.p. a (Showalter et al., 1996) b (Compton et al., 1993) This article has not been copyedited and formatted. The final version may differ from this version. 
